ACC: AstraZeneca unveils more SGLT2 heart benefits with latest batch of real-world data

When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress. In a study of more than 400,000 Type 2 diabetes patients, researchers drew an association between treatment with SGLT-2s—including AZ’s own Farxiga, J&J’s Invokana and Boehringer Ingelheim and Eli Lilly’s Jardiance—and a 32% lower risk of stroke.Original Article